Despite the suspension of the drug test by the World Health Organisation (WHO),The National Agency for Food and Drug Administration and Control (NAFDAC) says it will continue chloroquine clinical trials for COVID-19 treatment.
The NAFDAC director-general, Mojisola Adeyeye, disclosed this Tuesday during a programme on TVC.
This following WHO announcement which states that there would be a “temporary pause” in its solidarity trial on the use of hydroxychloroquine for treatment of COVID-19 patients.
Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
Adeyeye, however noted that there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the mild stage of the virus.
She revealed that the clinical trial in Nigeria would continue clinical trials which may take three to four months.
“There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” she said.
“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine.”
Recall on May 18, 2020, Fiona Braka, officer in charge of WHO in Nigeria, announced that the solidarity trial had started in Nigeria.